Scientific project design in drug discovery
BIO-494
Bibliography-Bio494
This page is part of the content downloaded from Bibliography-Bio494 on Sunday, 25 January 2026, 03:54. Note that some content and any files larger than 50 MB are not downloaded.
Description
Background reading
As mentioned in the course description, the following papers/books are considered background and should be read before the first session of office hours.
(Please find enclosed the articles)
Files and subfolders
- AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease.pdf
- Brown adipose tissue activity controls triglyceride clearance.pdf
- Computational approaches streamlining drug discovery.pdf
- Emerging Pharmacological Therapies for MASLD Targeting Hepatic Lipid Metabolism Pathways.pdf
- From NAFLD to MASLD genetics, pathophysiology and therapeutic implications.pdf
- Machine learning small molecule properties in drug discovery.pdf
- Screening for human ADMETox drug properties in drug discovery.pdf
- The Role of Absorption, Distribution, Metabolism, Excretion and Toxicity in Drug Discovery.pdf
- What ADME tests should be conducted for preclinical studies_.pdf
- ACC1 ACC2-Acetyl-CoA carboxylase inhibition reduces hepatic steatosis and fibrosis in NASH models.pdf
- AMPK Targeting AMPK-related signaling pathways opportunities and challenges for NAFLD therapy.pdf
- FASN TVB-2640 (denifanstat), a fatty acid synthase inhibitor, reduces liver fat in patients with nonalcoholic steatohepatitis in a randomized controlled trial.pdf
- PPARα Current Clinical Trial Status and Future Prospects of PPAR-Targeted Therapies in NAFLD NASH.pdf